Sunday, October 9, 2011

Transitioning to Chimera Research Group

To All Visitors & Subscribers,

I want to thank you for visiting over the past few years. It has been my pleasure to provide what I hope has been insightful trading strategies for the biotech and pharmaceutical sectors.

I am proud to announce that Jason Chew, Patrick Crutcher, Tro Khalijian, Richard Kursman and I have co-founded Chimera Research Group, where I will be serving as Trade Strategist. On Tuesday, October 11th, the site will officially launch.

Chimera Research Group will provide completely independent, actionable investment and trading ideas backed by comprehensive research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage will focus on early stage companies with impending FDA decisions or clinical trial results, in addition to mid-to-large cap bio-pharma companies with known catalysts.

I appreciate your patronage and I hope you will continue to follow my work at Chimera Research Group, where my co-founders and I will provide the best content available in the bio-pharmaceutical sectors. Please visit for more information.


Tony Pelz

Wednesday, March 30, 2011

Trading XenoPort's PDUFA Event

XenoPort Inc. (XNPT) is set to receive notification from the FDA on April 6 whether or not their restless leg syndrome drug Horizant is approved. I intend to trade this event using both a bullish and bearish approach – as of writing, however, I have only managed to execute the bullish side of the trade...

Read the full article here.

Thursday, March 24, 2011

Note About New Edition

I’ve received substantial questions regarding the new/updated edition of The Biotech Trader Handbook. Here are the answers to the most frequently asked questions:

(1) Is the book currently shown on Amazon ( the new/updated version?

Yes. I decided to issue this edition under the same ISBN# in order to retain the Amazon page ranking.

(2) If this is the new/updated edition, why does it have the same Table of Contents as the prior edition when using the “Look Inside” feature on Amazon?

It takes Amazon several weeks to upload the revised content for the “Look Inside” feature.

(3) Is an e-book version available for Kindle?

I am working with Amazon to get an e-book version available as soon as possible – I will make a note on the blog when this occurs.

If you have any additional questions, please feel free to e-mail me at: and I will do my best to answer them.


Monday, March 14, 2011

Latest Version of The Biotech Trader Handbook Now Available

The updated 2nd Edition of the Biotech Trader Handbook includes over 70 pages of new, value-added content on top of the existing content. This includes the following:

• Chapter 2.0, Trade Candidate Identification: This chapter was expanded to include recent developments in on-line resources and social media such as the use of Twitter, value-added blogs and full coverage websites.

• Chapter 4.0, Option Basics: This chapter was added to benefit readers without any prior knowledge of options. The chapter seeks to introduce the subject conceptually and from a trading perspective (i.e. practical, real life) and provides an initial basis to understand the more complex trade structures described later in the book.

• Chapter 5.0, Trading Strategy & Tactics: This chapter includes several new sections covering a wide variety of topics such as trading advisory panels and exiting illiquid (long) option positions (for example).

• Chapter 6.0, Trade Structures: This chapter includes four new (and innovative) trading structures on top of the existing eleven structures included in the prior version.

• Chapter 7.0, Trade Process: This chapter was added to provide the reader a simple process to identify low risk / high reward trades where there is no initial bullish, bearish or neutral trade conviction. Several trade examples are included.

The updated 2nd Edition can be purchased on Amazon:

Good luck with your trading!

Tony Pelz

Tuesday, March 8, 2011

HGSI: Trade Note

Human Genome Sciences (HGSI) is slated to receive a response from the FDA by Thursday, March 10, on whether or not its drug Benlysta is approved. I am trading this catalyst event using a Call butterfly spread with an overlaid tight long Call spread...To read the entire article, please click here.